PLETHICO

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release, dated November 28, 2008, titled "Plethico Pharmaceuticals Limited to acquire 20% stake in CIS Retail Pharmacy Chain Company ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_PR_28112008.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that "Plethico Pharmaceuticals Limited had entered into a Market Co-operation agreement with Shreya Life Sciences Private Limited on November, 2003 for a period of five years, whereby the entire range of Products of Plethico Pharmaceuticals Limited were retrained from being promoted/ marketed in Domestic Market." "The Non- Compete Agreement with Shreya Life Sciences Private Limited has ceased to be into effect w.e.f November, 2008".

News Verification : The media had reports that Plethico Pharmaceuticals Limited may pick up around 20% stake in a UAE based pharma retail chain with operations in the CIS region for around $ 20-22 million. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Plethico Pharmaceuticals Limited has vide its letter inter-alia stated, "We ourselves have not yet finalized anything pertaining to these business plans. There is n

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 31, 2008 with respect to the financial performance of the Company for the quarter ended September 30, 2008. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_PR-31102008.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 24, 2008 with respect to summary of the financial performance of the Company for the quarter ended June 30, 2008. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PLETHICO_PR_24072008.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that "The company has appointed Dr. Sharad Kasarle an eminent and distinguished professional having expertise in Neutraceutical and Herbal Products, as a "Consultant - Neutraceuticals" to look after and monitor R&D activities of Neutraceutical and Herbal segments". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/Plethico_Updates_15072008.zip target=NEW> For more detail

Plethico Pharmaceuticals Limited has informed the Exchange that Company's Corporate presentation have been compiled containing latest information regarding business overview, growth strategy, financial analysis etc. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/plethico_UP_30062008.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding the decisions taken at the Annual General Meeting of the members of the Company held on June 27, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_Outcome_27062008.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that:- "As an ongoing strategic move Plethico Pharmaceuticals Limited is ready to launch Natrol's entire range of herbal and nutraceutical products including "PROLAB", in its market including India, CIS, SEA and GCC. The said launch will done in phased manner".

News Verification : The media had reports that Plethico Pharmaceuticals Limited may acquire a US-based Nutraceuticals company for about $100 m. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Plethico Pharmaceuticals Limited has vide its letter inter-alia stated, "Answering to specific question by media, our CFO remarked that an organization such as ours is constantly on the look out for acquisitions, though we d

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors at their meeting held on May 27, 2008 considered the proposals and following decision were taken :- (1) that subject to the approval of the members in the forthcoming Annual General Meeting, the share capital of the Company be sub-divided each Equity Shares of Rs.10/- (Rupees Ten) into ten (10) Equity Shares of Rs.1/- (Rupees One) each. (2) that subject to the approval of the members in the forthcoming Annual General Meeting, the authorized share capital of the Company be increased from Rs.40,00,00,000 divid

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors at their meeting held on May 27, 2008 considered the proposals and following decision were taken: (1) That the Register of Members and Share Transfer Books will remains closed from June 24, 2008 to June 27, 2008 (both days inclusive) for the purpose of distribution of dividend to the members for the accounting year ended on December 31, 2007. (2) That Annual General Meeting of the members of the Company for the accounting year ended on December 31, 2007 scheduled to be held on June 27, 2008.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 27, 2008 has recommended dividend @25% i.e. Rs.2.50 per equity share of the Company.

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release towards summary of the financial performance of the Company for the quarter ended on March 31, 2008. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/plethico_PR_28042008.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on March 28, 2008 has approved the following : 1) Audited financial results of the Company for the quarter and 15 months accounting period ended on December 31, 2007. 2) Re-appointment of Shri Shashikant Patel and Shri Chirag Patel as Chairman & Managing Director and Whole-time Director & Chief Executive Officer of the Company respectively for a further period of 3 years w.e.f. April 01, 2008 at a remuneration as may be decided by the Board of Directors within the limits pr

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release towards summary of the financial performance of the Company for the quarter and 15 months accounting period ended on December 31, 2007. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_PR_28032008.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that "The Board of Directors of the Company at its meeting held on March 28, 2008 has approved the following: 1) Re-appointment of Shri Shashikant Patel and Shri Chirag Patel as Chairman & Managing Director and Whole-time Director & Chief Executive Officer of the Company respectively for a further period of 3 years w.e.f. 01.04.2008 at a remuneration as may be decided by the Board of Directors within the limits prescribed under Schedule XIII of the Companies Act, 1956 and subject to approval of members of the Company at the General Mee

Plethico Pharmaceuticals Limited has informed the Exchange that : "The manufacturing unit of the Company situated at Kandla Special Economic Zone has been awarded with the "Top Exporter Award" for the year 2006-07 for Chemicals, Drugs, Pharmaceuticals & Allied Sector by the Office of Development Commissioner, Kandla Special Economic Zone, Ministry of Commerce and Industry. The Top Exporter award has been received on behalf of the Company by Shri Hemant Modi, Chief Operating Officer of the Company at the 43rd Foundation Day celebrations on 7th March, 2008."

Plethico Pharmaceuticals Limited has informed the Exchange that: "The Board of Directors of the Company at its meeting held on 19.02.2008 has approved the following: (1) setting-up of State-of-the-Art manufacturing facility in the Dubai UAE (Middle East) through the wholly owned subsidiary (proposed name - Plethico International Limited) for the medical lozenges, NDDS Tablets/Capsules, Confectionary and allied products to cater the demand of the high volume emerging markets throughout the world. (2) Change in Compliance Officer of the company".

Plethico Pharmaceuticals Limited has informed the Exchange that the company's medicated lozenges and confectionery has always been a high revenue-earning generator and has been growing at a very fast space for all the markets including India. Due to tremendous growth in demand of the aforesaid segment, the company is facing capacity crunch and in view of this company is evaluating the best proposal location for this state-of-the-art manufacturing facility. The further details on the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements an

Plethico Pharmaceuticals Limited has informed the Exchange that "Mr. Ashok Mishra has been appointed as the "Company Secretary" and "Compliance Officer" of the Company w.e.f. 16/02/2008 in place of Mr. Pankaj Pabaiya, who has resigned from the Company w.e.f. 16/02/2008".

Plethico Pharmaceuticals Limited has informed the Exchange that: "The Company will publish the Quarterly/Yearly Audited Financial Results for the last quarter/year ending on 31st December, 2007, within a period of 3 months i.e. upto 31st March, 2008".

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release, titled "Plethico Pharmaceuticals Limited Completes Acquisition of Natrol, Inc.". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_PR_02012008.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that: "Mr. Ashok Sodhani, Non Executive Independent Director of the Company resigned from the Board of Directors of the Company with effect from 22nd November, 2007."

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 18, 2007, titled "Plethico Pharmaceuticals Limited to acquire USA's Natrol, Inc.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_Rel_19112007.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 31, 2007, titled " Plethico Pharmaceuticals Ltd. - Summary of Financial Performance for Quarter IV, 2006-07". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_PR_31102007.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated October 16, 2007, that: "Plethico Pharmaceuticals Limited today announced that it has successfully priced an offering of US$ 75 million by issue of foreign currency convertible bonds. The bonds have a zero coupon with tenor of 5 years and 1 day and are convertible into equity shares at a premium of 35% over the reference share price of Rs.447.95 (Closing price of the Shares on the National Stock Exchange Limited on October 15, 2007). Citigroup acted as the sole bookrunner to the transaction".

Plethico Pharmaceuticals Limited has informed the Exchange regarding the outcome of the Board Meeting held on October 01, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_BM_01102007.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that "The Company has shifted its Corporate Office to new location situated at :- "Sabnam House", Plot No. A/15-16, Cross Road No.2, MIDC, Andheri (E), Mumbai-400093; Phone No. : 91-022-66988301; Fax No. : 91-022-66988300 with immediate effect".

Plethico Pharmaceuticals Limited has informed the Exchange regarding details of utilizations of fund. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PlethicoPharma_UtilisationofFunds.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 18, 2007, titled " Plethico Pharmaceuticals Ltd. - Summary of Financial Performance for Quarter III, 2006-07". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PlethicoPharma_PR_18072007.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding details of utilizations of fund. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that the company has taken the following decision: That the company plans to do a possible acquisition in Germany in the Herbal segment. This will help the Company to strengthen the Herbal focus of the Company and also enable the marketing of herbal preparations in the Advanced Countries.

Plethico Pharmaceuticals Limited has informed the Exchange that the company has taken following decision: 1) The company has appointed M/s. Singhi Advisors Ltd. (formerly Singhi & Associates) as company's M&A Advisors on a Global level. The address of M/s. Sindhi Advisors is as under: 903, Raheja Centre, Nariman Point, Mumbai - 400 021, India. 2) The Company plans to do a possible acquisition of a minority stake in a CIS based retail pharmacy Chain Company. This acquisition will enable the company to de-basket it's credit risks in CIS and help move from Credit Market (distribution) to a Cash M

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of the Chairman's Speech at the Annual General Meeting held on March 30, 2007. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/plethico_cspeech_300307.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that "the 14th Annual General Meeting of the members of the Company held on Friday the 30th day of March 2007 at the Registered office of the Company and following decisions have been taken :- (1) Company has declared the dividend for the year 2005-06 of Rs. 2.50 per equity share i.e. @25%. (2) Mr. Ashok Sodhani, Dr. G.N. Qazi, Mr. Pramod K. Shrivastava and Mr. Abhay Suhane are appointed as Director of the Company. (3) The Board of Directors of the Company is authorized to decide sitting fees for attending the board meetings /compensa

Plethico Pharmaceuticals Limited has informed the Exchange that a meeting of the Board of Directors of the Company convened at a short notice, held on March 12, 2007 considered the proposals and following decision have been taken:- The equity holding in six subsidiary companies in CIS countries be partly hived off, out of equity held by the company in proportion stated hereunder at a premium of 40% over company's cost of acquisition, on the terms and conditions and on the consideration as set forth in the draft agreement, the draft of which was approved by the Board and initialed by the Chairm

Plethico Pharmaceuticals Limited has informed the Exchange that the Dividends, if sanctioned by the Members at the Annual General Meeting will be payable on and after 30.03.2007.

Plethico Pharmaceuticals Limited has informed the Exchange that: "The Board of Directors at their meeting held on Monday the 26th day of February, 2007 considered the proposals and following decision were taken:- 1) that the Register of Members and Share Transfer Books will remain closed from 27.03.2007 to 30.03.2007 (both days inclusive) for the purpose of distribution of dividend to the members for the year ended on 30.09.2006; 2) that the 14th Annual General Meeting of the members of the Company for the year ended on 30.09.2006 scheduled to be held on Friday the 30th day of March 2007 at th

Plethico Pharmaceuticals Limited has informed the Exchange that "The Status of utilization of IPO proceed upto 31.12.2006 is as under (Rs. in Crores) : (1) Proposed utilization as per prospectus :- Capital expenditure on different projects; Estimated cost Rs. in crores :- 117.17; Expenditure incurred up to 31.12.2006 Rs. in crores :- 33.48, (2) Proposed utilization as per prospectus :- Working Capital Requirement; Estimated cost Rs. in crores :- 27.50; Expenditure incurred up to 31.12.2006 Rs. in crores :- 27.49, (3) Proposed utilization as per prospectus :- Public Issue Expenses; Estimated co

Plethico Pharmaceuticals Limited has informed the Exchange that a meeting of the Board of Directors of the company was held on 28th December, 2006 and following major business were transacted during the course of such meeting - Noting of acceptance of resignation of Mr. Rakesh Jain from the Board of Director of the Company w.e.f 05th December, 2006.

News Verification : The media had reports that Plethico Pharmaceuticals Limited plans to acquire a contract manufacturing company and a retail pharmacy chain in the US. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Plethico Pharmaceuticals Limited has vide its letter inter-alia stated, "We would like to confirm that the news is absolutely correct as the company is pursuing many proposals related to the acquisitio

News Verification : The media had reports that Plethico Pharmaceuticals Limited plans to acquire a contract manufacturing company and a retail pharmacy chain in the US. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Reply is awaited from Plethico Pharmaceuticals Limited.

Plethico Pharmaceuticals Limited has informed the Exchange that "The Board of directors at their meeting considered and recommended a dividend @ 25% i.e. Rs. 2.50 per share for the year ended on 30th September, 2006".

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the company in its meeting held on November 29, 2006 at the Administrative office of the Company appointed Mr. Pramod Kishore Shrivastava and Mr. Abhay Suhane as Additional Directors of the Company to hold office upto the date of next Annual General Meeting. Mr. Sanjay Gupta, Additional Director of the Company resigned from the board w.e.f. November 29, 2006.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company in its meeting held on November 02,2006, appointed Dr. Gulam Nabi Qazi as an Additional Director of the Company.

Plethico Pharmaceuticals Limited has informed the Exchange that the Company will publish the Quarterly/Yearly Audited Financial Results for the last quarter/year ending on September 30,2006, within a period of 3 months i.e. upto December 31,2006.